Brokerages Set Oxford Biomedica plc (LON:OXB) Target Price at GBX 600.04

Shares of Oxford Biomedica plc (LON:OXB) have earned a consensus rating of “Buy” from the six analysts that are currently covering the firm, Marketbeat Ratings reports. Six equities research analysts have rated the stock with a buy recommendation. The average 12 month price objective among analysts that have issued a report on the stock in the last year is GBX 633.38.

A number of equities analysts recently commented on the company. Royal Bank Of Canada reduced their price objective on Oxford Biomedica from GBX 1,170 to GBX 1,140 and set an “outperform” rating on the stock in a research report on Wednesday, June 24th. Jefferies Financial Group restated a “buy” rating and issued a GBX 8.27 target price on shares of Oxford Biomedica in a report on Tuesday, June 2nd.

Oxford Biomedica Trading Down 0.5%

Shares of Oxford Biomedica stock opened at GBX 646 on Tuesday. The stock has a market cap of £781.90 million, a P/E ratio of -24.00 and a beta of 1.12. The stock’s 50 day simple moving average is GBX 616.45 and its 200-day simple moving average is GBX 664.55. Oxford Biomedica has a 1-year low of GBX 356 and a 1-year high of GBX 952. The company has a debt-to-equity ratio of 162.16, a current ratio of 2.20 and a quick ratio of 1.67.

About Oxford Biomedica

Oxford Biomedica (LSE: OXB) is a quality and innovation-led cell and gene therapy CDMO with a mission to enable its clients to deliver life changing therapies to patients around the world.

One of the original pioneers in cell and gene therapy, the Company has more than 25 years of experience in viral vectors; the driving force behind the majority of gene therapies. The Company collaborates with some of the world’s most innovative pharmaceutical and biotechnology companies, providing viral vector development and manufacturing expertise in lentivirus, adeno-associated virus (AAV) and adenoviral vectors.